Alto Neuroscience, Inc. (ANRO)
ANRO moved a median of +0.19% 30 minutes after news, and +0.49% by the close. How ANRO actually reacts to news — the realized, point-in-time move the market made, measured across 959 labeled events over the last three years with zero look-ahead.
ANRO’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 45% | 902 |
| 30-min | +0.19% | 54% | 955 |
| 60-min | +0.24% | 54% | 958 |
| to close | +0.49% | 55% | 929 |
| Middle 50% of ANRO reactions | -0.81% to +1.40% |
|---|---|
| Median reaction (30-min) | +0.19% |
| Measured reactions | 959 |
Half of all Alto Neuroscience, Inc. news events land between -0.81% and +1.40% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ANRO reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 32 | -1.91% | 28% | -4.18% |
| Rating reiterations | 48 | +0.40% | 60% | -0.60% |
| Price-target raises | 10 | +0.33% | 60% | +0.46% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how ANRO ranks against every other measured name →
That’s how ANRO usually reacts — get an email when it moves on news →Email me when ANRO moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ANRO's baseline. Nothing else.
Recent ANRO events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Alto Neuroscience Announces Participation in Upcoming Investor Conferences | Press release | Business Wire | +1.32% | -3.97% | |
| Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer | Press release | Business Wire | +1.86% | +0.37% | |
| Form 8-K Alto Neuroscience, Inc. For: Aug 26 | SEC filing · Form 8-K | SEC EDGAR | +1.86% | +0.37% | |
| Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | Business Wire | +4.77% | +7.67% | |
| Form 10-Q Alto Neuroscience, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.77% | +7.67% | |
| Form 8-K Alto Neuroscience, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +4.77% | +7.67% | |
| Form 8-K Alto Neuroscience, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -1.49% | -2.87% | |
| Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock | Press release | Business Wire | -2.06% | +5.97% | |
| Form 8-K Alto Neuroscience, Inc. For: Jul 13 | SEC filing · Form 8-K | SEC EDGAR | -2.06% | +5.97% | |
| Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia | Press release | Business Wire | -1.31% | -2.89% | |
| Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors | Press release | Business Wire | -1.42% | -1.22% | |
| Form 8-K Alto Neuroscience, Inc. For: May 27 | SEC filing · Form 8-K | SEC EDGAR | -1.42% | -1.22% | |
| Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award | Press release | Business Wire | +0.67% | -0.26% | |
| Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights | Press release | Business Wire | -1.11% | -4.35% | |
| Form 10-Q Alto Neuroscience, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.11% | -4.35% | |
| Form 8-K Alto Neuroscience, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +1.77% | +7.23% | |
| Form 8-K Alto Neuroscience, Inc. For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -1.11% | -4.35% | |
| Alto Neuroscience Announces Participation in Upcoming Investor Conferences | Press release | Business Wire | -2.52% | +0.12% | |
| Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting | Press release | Business Wire | -1.49% | +0.28% | |
| Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | Press release | Business Wire | -1.27% | -5.71% | |
| Form EFFECT Alto Neuroscience, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.27% | -5.71% | |
| Form S-3 Alto Neuroscience, Inc. | SEC filing · Form S-3 | SEC EDGAR | +2.58% | +13.49% | |
| Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements | Press release | Business Wire | +6.62% | +11.24% | |
| Form 8-K Alto Neuroscience, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +6.62% | +11.24% | |
| Form ARS Alto Neuroscience, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -1.40% | -0.97% | |
| Form DEF 14A Alto Neuroscience, Inc. For: May 12 | SEC filing · Form DEF | SEC EDGAR | -1.40% | -0.97% | |
| Form DEFA14A Alto Neuroscience, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -1.40% | -0.97% | |
| Alto Neuroscience Announces $120 Million Private Placement Financing | Press release | Business Wire | +1.75% | +7.86% | |
| Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights | Press release | Business Wire | +1.75% | +7.86% | |
| Form 10-K Alto Neuroscience, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.75% | +7.86% | |
| Form 8-K Alto Neuroscience, Inc. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | +1.75% | +7.86% | |
| Form S-8 Alto Neuroscience, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.75% | +7.86% | |
| Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum | Press release | Business Wire | +0.00% | +0.18% | |
| Alto Neuroscience Announces Participation in Upcoming Investor Conferences | Press release | Business Wire | +4.71% | +4.99% | |
| Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia | Press release | Business Wire | +1.19% | +0.54% | |
| Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment | Press release | Business Wire | +0.00% | +0.69% | |
| Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression | Press release | Business Wire | -0.48% | +3.56% | |
| Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology | Press release | Business Wire | -0.35% | -4.84% | |
| Form EFFECT Alto Neuroscience, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -1.33% | +2.44% | |
| Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08 | Press release | Business Wire | +0.00% | -0.89% | |
| Form S-3 Alto Neuroscience, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.52% | +2.21% | |
| Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Press release | Business Wire | +2.56% | +6.77% | |
| Form 10-Q Alto Neuroscience, Inc. For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.56% | +6.77% | |
| Form 8-K Alto Neuroscience, Inc. For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +2.56% | +6.77% | |
| Alto Neuroscience to Participate in Upcoming Investor Conferences | Press release | Business Wire | +2.05% | +11.46% | |
| Form D Alto Neuroscience, Inc. | SEC filing · Form D | SEC EDGAR | +2.05% | +11.46% | |
| Alto Neuroscience Announces $50 Million Private Placement Financing | Press release | Business Wire | +8.17% | +63.45% | |
| Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting | Press release | Business Wire | +8.17% | +63.45% | |
| Form 8-K Alto Neuroscience, Inc. For: Oct 19 | SEC filing · Form 8-K | SEC EDGAR | -1.44% | -1.00% | |
| Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia | Press release | Business Wire | +14.97% | +43.24% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ANRO section they belong to.
Where else ANRO is measured.
ANRO earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alto Neuroscience, Inc.'s median reaction calculated?
Every labeled ANRO news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 959 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of ANRO's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ANRO's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.